Study on the mechanism of echinacoside in preventing and treating hypoxic pulmonary hypertension based on proteomic analyses
- PMID: 39401152
- PMCID: PMC11472809
- DOI: 10.1002/prp2.70025
Study on the mechanism of echinacoside in preventing and treating hypoxic pulmonary hypertension based on proteomic analyses
Abstract
Hypoxic pulmonary hypertension (HPH), a chronic condition affecting the cardiopulmonary system, has high mortality. Echinacoside (ECH) is a phenylethanoid glycoside, which is used to ameliorate pulmonary vascular remodeling and pulmonary vasoconstriction in rats. Accordingly, we aimed to explore the mechanism of ECH in preventing and treating HPH. Sprague Dawley rats were housed in a hypobaric hypoxia chamber for 28 days to obtain the HPH model. The experimental rats were randomly allocated into the following several groups: normoxia group, chronic hypoxia group, and ECH group. The therapeutic results of ECH (10, 20, and 40 mg/kg) showed that ECH reduced mPAP, Hb, Hct, and RVHI in HPH rats. Then this work employed label-free quantitative proteomic analysis, western blotting, and RT-PCR to investigate the mechanism by which ECH prevents HPH. The results found that in the chronic hypoxia group, the levels of ACSL1, COL6A1, COL4A2, COL1A1, and PC increased compared to the normoxia group. However, the opposite effect was observed in the chronic hypoxia group treated with ECH. The study indicates that the administration of ECH may slow the pathological progression of HPH by suppressing the inflammatory response, inhibiting smooth muscle cell proliferation, and minimizing the deposition of extracellular matrix.
Keywords: cell proliferation; echinacoside; hypoxic pulmonary hypertension; inflammation; proteomics.
© 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures







Similar articles
-
Echinacoside prevents hypoxic pulmonary hypertension by regulating the pulmonary artery function.J Pharmacol Sci. 2020 Dec;144(4):237-244. doi: 10.1016/j.jphs.2020.09.002. Epub 2020 Sep 10. J Pharmacol Sci. 2020. PMID: 33070843
-
Exosomes derived from mesenchymal stromal cells exert a therapeutic effect on hypoxia-induced pulmonary hypertension by modulating the YAP1/SPP1 signaling pathway.Biomed Pharmacother. 2023 Dec;168:115816. doi: 10.1016/j.biopha.2023.115816. Epub 2023 Nov 2. Biomed Pharmacother. 2023. PMID: 37918254
-
Luteolin ameliorates hypoxic pulmonary vascular remodeling in rat via upregulating KV1.5 of pulmonary artery smooth muscle cells.Phytomedicine. 2024 Sep;132:155840. doi: 10.1016/j.phymed.2024.155840. Epub 2024 Jun 22. Phytomedicine. 2024. PMID: 38941817
-
Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats.J Ethnopharmacol. 2018 Apr 24;216:175-183. doi: 10.1016/j.jep.2018.01.010. Epub 2018 Jan 8. J Ethnopharmacol. 2018. PMID: 29325918
-
The effect of activated κ-opioid receptor (κ-OR) on the role of calcium sensing receptor (CaSR) in preventing hypoxic pulmonary hypertension development.Biomed Pharmacother. 2020 May;125:109931. doi: 10.1016/j.biopha.2020.109931. Epub 2020 Feb 14. Biomed Pharmacother. 2020. PMID: 32066040
References
-
- Veith C, Vartürk‐Özcan I, Wujak M, et al. SPARC, a novel regulator of vascular cell function in pulmonary hypertension. Circulation. 2022;145:916‐933. - PubMed
-
- Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618‐3731. - PubMed
-
- Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327:1379. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous